ÂÜÀòÂÒÂ×

Andreas Seidl has an extensive work experience in the pharmaceutical industry. Andreas currently serves as the Chief Scientific Officer at Formycon AG since 2022. Prior to that, they held the position of Chair of the Scientific Advisory Board at Leukocare AG starting from 2019. Andreas also served as the Chief Operating Officer at Leukocare AG from 2019 to 2022.

Before their time at Leukocare AG, Andreas worked at Novartis from 2015 to 2019, where they held the role of Head Global Analytical Characterization & Bioanalytics. Andreas also worked at Hexal AG/Sandoz, where they were responsible for Analytical Characterization and served as the Site Head Oberhaching from 2010 to 2015. At Hexal AG/Sandoz Biopharmaceuticals, they were the Head of Analytics & Quality Control from 2002 to 2010. Andreas also held the role of Head of Analytical Development at Hexal Biotech GmbH in 2002.

Throughout their career, Andreas has gained valuable experience and expertise in the pharmaceutical industry, specifically in scientific research, advisory roles, and analytical characterization.

Andreas Seidl completed their education at the University of Konstanz from 1997 to 2001. During this period, they pursued a degree in Biochemistry with a specialization in Protein analytics and mass spectrometry. Andreas successfully attained the academic title of Dr. rer. nat. upon completing their studies.